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Patients with head and neck cancer have to deal with the impact of treatment on its functional 
and aesthetic aspects, and its self-report enables improvements in clinical and social support.
Objective: To evaluate the quality of life of patients dealing with squamous cell carcinoma of the 
head and neck.
Method: A prospective analytical study. Twenty nine patients with mean age of 57 years answered at 
three stages: onset, middle and end of treatment, the questionnaires: Quality of Life Core Question-
naire - Cancer 30 and the Quality of Life Questionnaire - Head and Neck, the European Organization 
for Research and Treatment of Cancer. We used the Friedman test at: 0.05.
Results: There were high mean values concerning physical, cognitive, social functions; improve-
ments in general health and social function decline during treatment; and a significant difference in 
taste and smell (p = 0.020), swallowing (p = 0.040), cough (p = 0.013) and weight loss (p = 0.011).
Conclusion: There was a significant reduction in the quality of life for some common symptoms 
resulting from cancer treatment, which was not seen in the evaluation of the aspects related to 
physical, cognitive and social functions, and general health.
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INTRODUCTION
In Brazil, for the year of 2012, there are estimates 
of 518,510 new cases of cancer, 20,280 of them in the 
mouth and larynx1. The term Head and Neck Cancer is 
defined on anatomical and topographical bases to des-
cribe malignant tumors of the upper aerodigestive tract, 
including the oral cavity, pharynx and larynx. The most 
common histological type is the squamous cell carcino-
ma, present in more than 90% of the cases2,3. Smoking 
and drinking, when together, have a synergic effect, 
increasing in 30 fold the risk of the patient developing 
this type of cancer3.
Patients with head and neck cancer, besides 
harboring a disease which threatens their lives, have 
to deal with the impact of treatment on functional and 
aesthetic aspects4. This region is the anatomical site of 
basic functions, such as speech, swallowing, hearing, 
breathing, associated with social interaction, which are 
of vital importance to the individual4-6.
Treatment may be carried out by means of surgery, 
almost always associated with radiotherapy. Chemothera-
py and immunotherapy are relevant adjuvant therapies7,8. 
Surgery may cause permanent mutilations, loss of organs 
and/or changes to their functions. Radiotherapy, with or 
without chemotherapy may cause transient side effects, 
which subside at the end of treatment; nonetheless, 
very much limiting to the patient7,9-11. Changes to the 
appearance, voice and difficulties swallowing, when 
present, bring varied degrees of limitations4,9-15. Local 
pain, dyspnea, often times followed by a yellowish, 
thick and smelly secretion, intermittent cough, chronic 
fatigue, changes to olfaction, stress, depression and 
difficulties accepting one’s body image; all play in the 
patient’s loss of self-esteem and social isolation. This, 
and other factors associated with complications, such as 
mucositis, xerostomia, changes to the sense of taste and 
infections stemming from the cancer therapy, may all 
trigger a negative impact on the quality of life of these 
individuals4,14-23.
Quality of life is the way with which the individual 
faces the different aspects of his/her life as a whole. It 
is associated with the individual’s degree of satisfaction 
found in family life, love life, social and environmental 
life, and the very existential sense1,3,4,15,24,25. To assess 
the quality of life of the patients affected by malignant 
neoplasia is important to better understand the impact of 
the disease and its treatment in the patient’s daily routine, 
and improve the care protocol with more encompassing 
clinical, social and rehabilitation support measures8,24.
The goal of the present study was to assess the 
quality of life of patients with squamous cell carcinoma 
in the head and neck, submitted to oncologic treatment.
METHOD
Analytical, prospective study, carried out in three 
stages of the antineoplastic treatment: onset, middle 
and final. We included patients with a histopathological 
diagnosis of squamous cell carcinoma only in a primary 
lesion of the head and neck; seen between July of 2010 
and June of 2012; with ages equal to or greater than 
40 years; who were cognitively able to understand and 
answer the questions and who had not received previous 
treatment for this lesion.
In order to assess the patient’s cognitive capa-
city, we employed the Mini Mental State Examination 
(MMSE)26 questionnaire. We took off the patients with 
any type of malignant neoplasia, age below 40 years 
and who did not have cognitive capacity and were able 
to communicate.
The patients who accepted to participate in the 
study and signed the Informed Consent Form, were re-
ferred to a dentist who had been trained to collect the 
data. The patients answered the questionnaires on the 
day of the first visit with the dentist and established, 
then, the second endpoint for the second deployment 
of the questionnaire. The third endpoint was the end 
of the cancer treatment, when the patient was dischar-
ged. Data regarding the disease was collected from the 
hospital medical chart. The patient answered the two 
questionnaires at the same time: the EORTC Quality of 
life questionnaire (QLQ-C 30)27 and the Quality of Life 
Questionnaire-Head and Neck (QLQ-H&N35)28 from the 
European Organization for the Research and Treatment 
of Cancer - EORTC group, and authorized its use for 
this study, they were validated in Brazil24. The authors 
advocated the application of the two instruments, 
which are complementary. The QLQ-C30 encompasses 
30 questions grouped into five functional scales, nine 
scales associated with symptoms and a global scale. The 
QLQ-H&N35 has 35 questions - 30 which are grouped 
in 13 scales and five of simple answer. It approaches 
symptoms associated with the specific tumor location, 
side effects associated with the treatment provided and 
additional quality of life aspects affected by the disease 
or its treatment.
The answers were converted into a linear scoring 
scale, with values between 0 and 100, as per advocated 
by EORTC27,28. The results were expressed in mean values, 
with their respective confidence intervals. A high score 
in the questions associated with the symptoms reflects 
their more intense presence, while a high score in the 
questions associated with function reflects the better life 
condition of the patient.
The dentist followed the patient throughout treat-
ment, and adjusted the date of the second data collection 
when treatment was delayed. The participants of this study 
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received dental treatment prior to the cancer treatment, 
treatment of the oral lesions stemming from the radio and/
or chemotherapy and prosthesis rehabilitation treatment 
after the cancer treatment, when indicated.
We used the Statistical Package for the Social 
Sciences, SPSS software, version 17 and we used the 
Friedman’s test for paired samples, with a 0.05 signifi-
cance level.
The study followed the ethical recommendations 
for studies with human beings, established in Resolu-
tion # 196/96 from the National Health Council, having 
been approved by means of Ordinance # 2187/10 from 
the Ethics in Research Committee. There were no risks 
for the individuals involved in the study, guaranteeing 
confidentiality and secrecy concerning the information 
provided by the participants.
RESULTS
In the study we had 29 patients with ages between 
43 and 74, mean age of 57 years, between 2010 and 2012. 
Most of the patients were men (82.8%), married (75.9%), 
brown in color (44.8%), coming from other cities of Minas 
Gerais and referred to treatment in Montes Claros (82.7%), 
with low schooling (69.0%), rural workers (31.0%), low 
income, exposed to at least one risk factor (95.5%), almost 
all were smokers and alcohol drinkers (63.5%).
Tumor size was assessed according to the TNM 
classification29, and T3 and T4 corresponded to 45.2% of 
the cases. The primary lesion was more frequently located 
on the tongue or pharynx (22.7% each), followed by the 
larynx (18.2%), lips (13.6%) and palate, ear or vocal folds 
(4.5% each). Concerning the cancer treatment employed, 
most of the patients were submitted to radiotherapy only 
(44.5%), followed by combined treatment with chemo 
and radiotherapy (33.3%) and surgery and radiotherapy 
(18.5%), besides surgery, radiotherapy and chemotherapy, 
combined (Table 1).
Table 2 shows the mean scores of functions and 
symptoms for general quality of life, the QLQ-C30, 
comparing the three prospective cohorts. There were 
no statistically significant differences among the three 
moments for any of the functions or symptoms. We see 
that high mean scores for the patient’s functions suggest, 
in a general view, low disease impact on the physical, 
emotional, cognitive and social functions, and personal 
role performance. There was an improvement in the 
general health status and decline of the social function 
throughout the treatment. The personal role performance 
was lower in the middle of treatment and the emotional 
function was assigned the lowest mean value among 
all the functions. Considering the scale of symptoms, 
the occurrence of insomnia was higher at treatment on-
set; however, nausea, vomit, pain, loss of appetite and 
constipation were higher in the middle of the treatment. 
Table 1. Patient distribution according to socio-economic 
and demographic characteristics and treatment type. Montes 
Claros, 2010-2012.
Variable n %
Gender
Male 24 82.8
Female 05 17.2
Age range
≤ 50 years 04 13.8
51 a 60 years 13 44.8
> 60 years 12 41.4
Skin color
White 11 37.9
Brown 13 44.8
Black 05 17.2
Marital status
Single 02 6.9
Married/stable union 22 75.9
Divorcee/separated 04 13.8
Widow/widower 01 3.4
Income*
No income 01 3.8
< 1 m.w. 07 26.9
1 to 3 m.w. 18 69.2
Years of schooling
Illiterate/semi-illiterate 10 34.5
≤ 4 years 10 34.5
5 a 8 years 06 20.7
9 a 12 years 02 6.9
> 12 years 01 3.4
Occupation
Public servant 01 3.4
Worker in the private sector 02 6.9
Autonomous professional 03 10.3
Domestic worker 01 3.4
Rural worker 09 31.0
General service 02 6.9
Retiree 08 27.6
Without occupation 03 10.3
Treatment type*
Surgery + Radiotherapy 04 18.5
Chemotherapy + Radiotherapy 09 33.3
Surgery + Chemotherapy + Radiotherapy 01 3.7
Radiotherapy alone 12 44.5
Total 29 100.0
* Three patients without information; n total = 29 patients; n = absolute 
frequency; % = relative frequency. m.w.= minimum wage
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At the end of treatment, we found a higher rate of fatigue, 
dyspnea, diarrhea and financial difficulties.
DISCUSSION
The sociodemographic and economical aspects 
of the participants in this investigation are in agreement 
with the epidemiological profile of head and neck cancer 
found in the literature, men older than 45 years, brown 
skin, rural workers exposed to at least one risk factor, 
such as exposure to sunlight, smoking or alcohol, with 
low economical situation1.
Of all the patients assessed, 44.5% were eligible 
to radiotherapy only, and 33.3% were treated with radio-
therapy associated with chemotherapy. Technological 
progresses concerning radiotherapy procedures and the 
new chemotherapy protocols have favored the choice 
of theses means of treatment. Nonetheless, there is the 
risk of increasing toxicity induced by chemo-radiation 
Table 2. EORTC QLQ C30 of patients with cancer assessed 
at the onset, middle and end of treatment. Montes Claros, 
2010-2012.
Items of scale
Treatment period
p-value*Onset Middle Post
Mean (SD) Mean (SD) Mean (SD)
Functions
Physical 
function 81.6 (19.7) 83.3 (25.3) 83.3 (25.3) 0.751
Emotional 
function 76.5 (29.8) 84.3 (13.5) 77.9 (21.6) 0.502
Cognitive 
function 91.7 (18.3) 95.8 (7.4) 91.7 (17.2) 0.861
Social function 91.2 (15.7) 90.2 (15.7) 81.4 (27.6) 0.291
Role 
performance 86.3 (16.9) 75.5 (22.9) 82.4 (29.1) 0.079
Symptoms
Fatigue 17.0 (23.3) 13.1 (18.9) 18.3 (30.2) 0.926
Nausea and 
vomits 4.9 (11.4) 12.7 (24.7) 6.9 (20.5) 0.200
Pain 21.6 (29.3) 23.5 (26.4) 17.6 (19.9) 0.979
Dyspnea 6.3 (18.1) 12.5 (26.9) 18.8 (32.1) 0.368
Insomnia 27.5 (35.8) 7.8 (14.6) 13.7 (29.0) 0.182
Loss of 
appetite 13.7 (29.0) 25.5 (38.2) 19.6 (39.2) 0.710
Constipation 2.0 (8.0) 19.6 (35.7) 11.8 (28.7) 0.180
Diarrhea 1.9 (8.1) 1.9 (8.1) 9.8 (25.7) 0.368
Financial 
difficulty
25.5 (36.4) 19.6 (29.0) 33.3 (40.8) 0.168
General health 
status /QoL 66.7 (23.0) 70.1 (16.7) 71.7 (20.4) 0.280
*Friedman’s test for paired samples, with a 0.05 significance level; SD: 
standard deviation; p-value = descriptive level of the Friedman’s test; 
n total = 29 patients.
Table 3. QLQ-H&N35 of patients assessed with cancer at 
the onset, middle and end of the treatment. Montes Claros, 
2010-2012.
Scale items 
Symptoms
Treatment period
p-value*Onset Middle After
Mean (SD) Mean (SD) Mean (SD)
Pain 15.6 (20.0) 23.4 (20.0) 19.8 (21.5) 0.288
Senses (taste 
and smell 11.5 (20.8) 32.3 (33.0) 36.5 (39.5) 0.020
Swallowing 12.3 (23.8) 24.5 (29.4) 21.1 (30.6) 0.040
Problems with 
speech 12.5 (17.2) 21.5 (26.4) 22.2 (28.4) 0.756
Social/feed 
problems 7.4 (14.1) 18.1 (25.7) 20.6 (29.3) 0.239
Interact 
difficulties
11.6 (19.1) 5.8 (7.5) 8.4 (13.9) 0.836
Sexuality 20.0 (27.6) 30.0 (34.6) 31.1 (42.7) 0.236
Problems w/ 
teeth 27.5 (39.5) 37.3 (48.4) 33.3 (42.9) 0.682
Difficulty 
opening mouth 19.6 (35.5) 29.4 (37.0) 33.3 (37.3) 0.209
Dry mouth 21.5 (20.2) 31.4 (29.9) 31.4 (39.9) 0.689
Sticky saliva 21.6 (26.2) 29.4 (37.0) 29.4 (35.1) 0.717
Cough 9.8 (15.6) 58.8 (67.7) 37.2 (35.1) 0.013
Feels sick 15.7 (20.8) 15.7 (23.9) 19.6 (33.4) 0.975
Takes 
analgesic 41.2 (50.7) 52.9 (51.4) 35.3 (49.2) 0.529
Food 
supplement 5.9 (24.1) 5.9 (24.2) 23.5 (43.7) 0.165
Feeding with a 
probe 5.9 (24.3) 11.8 (33.2) 11.8 (32.2) 0.779
Weight loss 29.4 (46.9) 64.7 (49.3) 64.7 (49.2) 0.011
Weight gain 23.5 (43.7) 23.5 (43.5) 47.1 (51.4) 0.202
* Friedman’s test for paired samples at a significance level of 0.05; 
SD= standard deviation; p-value = descriptive level of the Friedman’s 
test; n total = 29 patients.
The QLQ-H&N35 specific questionnaire, in de-
tails on Table 3, shows a difference between the three 
moments during treatment, highly significant for taste 
and smell (p = 0.020), deglutition (p = 0.040), cough 
(p = 0.013), and weight loss (p = 0.011). Difficulty of 
interaction happened especially at treatment onset, 
with a mean value of 11.6. Pain and swallowing, den-
tal problems, cough and the use of analgesics - were 
symptoms of higher impact in the middle of treatment. 
At the end of treatment, the use of food supplements, 
difficulties to open one’s mouth, greater changes in 
senses (olfaction and taste), speech disorders, social 
difficulties in feeding, loss in sex drive and a feeling of 
being sick, had the higher mean values in relation to 
the other two moments during treatment.
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with painful and debilitating effects, which can cause the 
need to interrupt treatment, compromising the diagno-
sis of the patient3,6,30. Different treatment modalities for 
some tumor sites in the head and neck may bring about 
survival results and similar disease control, however, 
with different complications, sequelae and functional 
results. These induced effects and sequelae may nega-
tively influence the quality of life of individuals which 
could, in the future, help in clinical judgment and the 
definition of the treatment approaches. In this context, the 
interest for the quality of life of these patients is directly 
associated with the day-to-day care practices in health 
centers3,7,14,15,18,23,25,31,32.
There were no statistically significant differences 
between the three moments for no function or symptom 
in the QLQ-C30 questionnaire assessment (Table 2). The 
mean scores of the functions assessed were high in the 
treatment onset, and changed very little prospectively. In 
a similar fashion, the global quality of life did not suffer 
any significant change. Similar results were found by 
Braam et al.6 in the assessment of 44 patients submitted 
to neck-facial radiotherapy only, or adjuvant to surgery. 
Notwithstanding, Bansal et al.30, assessed 45 patients with 
indications for head and neck radiotherapy, and showed 
a correlation between the worsening of the physical 
function and an increase in symptoms such as: fatigue, 
pain, loss of appetite. Blanco et al.12 showed an increase 
in the symptoms scale (pain, fatigue and weight loss) 
and decline on the functional scale, with loss of physical, 
social and emotional functions and role performance. In 
the present study, except for pain and insomnia, none 
of the symptoms returned to their baseline values upon 
treatment discharge.
We found a low disease impact on their physical, 
emotional, cognitive and social functions and personal 
role performance, different from Scharloo et al.33, in a 
prospective study involving 177 patients, in which there 
was an improvement in the emotional function and a 
worsening in social function throughout the follow up 
period. The patients from Montes Claros had the lowest 
mean value for the emotional function among all the 
functions; nonetheless, there was a large data variation 
prospectively, which may reflect the large subjectivity 
of these parameters. Moreover, there was a drop in the 
social function throughout treatment. In one study car-
ried out by Connor et al.4, the patients had a progressive 
worsening of their physical function, contrasting with this 
study, in which there was an improvement in this func-
tional scale throughout the period, and an improvement 
in their general health status.
Social interaction was more impaired at the onset 
of the anti-cancer treatment and improved in the middle 
of the treatment (Table 3). Opposite results were found 
by Ohrn et al.34 using the same questionnaires in the 
assessment of 18 patients. According to the authors, 
feeding and social contact had higher intra and post-
-radiotherapy mean values.
Comparing mean values at the end of treatment 
to the values found at treatment onset and middle of the 
treatment in the QLQ-H&N35 questionnaire assessment 
(Table 3), there is an increase in dry mouth, saliva viscosity 
with a significant swallowing impairment (p = 0.040). This 
can be partly associated to the surgical procedures utilized 
in the treatment of head and neck tumors5, although the 
number of patients operated in this sample is small. Other 
possible factors participating are the greater presence of 
primary tumors in aerodigestive sites, such as the tongue 
and pharynx (22.7% each), and non-surgical treatment, 
such as chemo-radiotherapy, in organ preservation pro-
tocols5. The increase in nausea and vomit symptoms, loss 
of appetite and constipation seen during the middle of the 
treatment may be associated with the appearance of the 
classic radio and chemo-induced acute affects.
Another common complication is dysgeusia, dis-
torted or impaired sense of taste, affecting 50% to 75% 
of those submitted to radiotherapy, chemotherapy, or 
both14,35. There was a reduction in taste and olfaction in 
the three periods assessed (11.5-32.3-36.5, respectively, 
with a p = 0.020). It is believed that this worsening in taste 
happens with the cumulative dose of radiation14,35. About 
15% of these individuals continue to have dysgeusia, even 
after the end of treatment14,35-37. These symptoms may have 
contributed to the progressive weight loss reported by the 
patients (p = 0.011).
A proper nutrition is important and needs to be 
stimulated and facilitated35-37, despite the increase in using 
food supplements at the end of the oncologic treatment 
(Table 3). Changes to olfaction and taste associated with 
the difficulty in opening ones mouth and feeding-related 
social difficulties may have contributed to the increase in 
using food supplements. Blanco et al.12 found a greater 
occurrence of changes in the sense, especially after 3 
months of the surgery; however, with partial improvement 
after 6 months.
In our study, pain was present in the three mon-
ths of the assessment, with similar responses in the two 
questionnaires. It is predominant in the middle of the 
treatment, and it declines at its end. The high standard 
deviation from the mean suggests a large variability in 
its perception. The pain increase during treatment may 
be due to adverse opportunistic lesions arising from the 
radiotherapy and/or the chemotherapy, which may justify 
the increase in analgesic medication use (Table 3). Pain is 
common in patients with head and neck cancer. It is repor-
ted by about half of the patients before cancer treatment, 
by 81% of them during treatment, by 70% at the end and 
by 36% six months or more after treatment38. It may be a 
consequence of the curative treatment associated with the 
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malignancy, to physical and psychological suffering, and 
because of nociceptive and neuropathic mechanisms. In 
some cases, pain is a coincidence which is not directly 
associated with the cancer38.
To assess the quality of life of cancer patients 
is complex, considering the large number of variables 
which impact the patient’s self-perception, from their 
social situation all the way to the very particularities of 
their diseases. It encompasses individual assessment 
characteristics, which does not depend on the patient’s 
system of beliefs, values and even physical strength3,5,15. 
For these reasons, it is a fundamental tool used to assess 
the impact of the disease and its treatment obtaining 
epidemiological evidence which support changes to a 
more effective multiprofissional support protocol for 
the patients5,8,17,19,24.
CONCLUSION
There was a significant quality of life reduction 
for the patients throughout treatment in relation to some 
common symptoms in the treatment of cancer, which 
did not occur in the assessment of the aspects associated 
with the social, cognitive and physical functions. It is 
necessary that the multidisciplinary team use information 
obtained in this investigation in order to build a broader 
care protocol, involving demands arising from symptoms 
and life situations.
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